Generex Biotechnology Corporation's Oral-lyn Phase III Dossier submitted for ...
News | 24 January 2013
Jan 24, 2013 (Menafn - M2 EQUITYBITES via COMTEX) --Drug delivery company Generex Biotechnology Corporation GNBT revealed on Wednesday the submission of a dossier of the results of the Phase III trial of its Generex Oral-lyn seeking approval of the ...
Click on the link to read the full article at MENAFN.COM
(This link will open in a new window)
- US Supreme Court says patent settlement can "sometimes" be illegal
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
